ACN Newswire

Sat Sep 5

Avance Clinical Client Immunic, Inc. Announced Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function

Written by ACN Newswire

Adelaide, AUS, Sep 4, 2020 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that its client Immunic Therapeutics has announced dosing of the first healthy volunteer in the company's phase 1 clinical program of...

Read more: Avance Clinical Client Immunic, Inc. Announced Dosing of First Healthy Volunteer in Phase 1...

ACN Newswire

Avance Clinical Client Immunic, Inc. Announced Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function

Richard Hardigan, The Other Side of the Wall

From the editor: get your coronavirus analysis and advice direct from the experts

Time doesn't heal all wounds: how DNA damage as we age causes cancer

Sustainable shopping: your guilt-free guide to flowers this Valentine's Day

As we celebrate the rediscovery of the Endeavour let's acknowledge its complicated legacy

The key to the success of the $130 billion wage subsidy is retrospective paid work

Another COAG meeting, another limp swing at the waste problem

The live export trade is unethical. It puts money ahead of animals' pain

Teleworkability in Australia: 41% of full-time and 35% of part-time jobs can be done from home

Media receives some government relief after coronavirus hit

Australia is vulnerable to a catastrophic cyber attack, but the Coalition has a poor cyber security track record